James Roach

1.6k total citations
35 papers, 1.1k citations indexed

About

James Roach is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Oncology. According to data from OpenAlex, James Roach has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Physiology and 7 papers in Oncology. Recurrent topics in James Roach's work include Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (8 papers) and Sleep and related disorders (5 papers). James Roach is often cited by papers focused on Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (8 papers) and Sleep and related disorders (5 papers). James Roach collaborates with scholars based in United States, United Kingdom and Canada. James Roach's co-authors include David A. Amato, Robert Rubens, Kendyl Schaefer, Thomas Roth, Yancy Y. Phillips, Gregory J. Argyros, Andrew D. Krystal, Martin B. Scharf, James E. Bredfeldt and Terrance J. Ball and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

James Roach

35 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Roach United States 18 322 311 302 279 175 35 1.1k
Gail Murphy United States 16 120 0.4× 175 0.6× 65 0.2× 127 0.5× 249 1.4× 23 1.0k
Heiner Mönig Germany 18 134 0.4× 115 0.4× 86 0.3× 54 0.2× 59 0.3× 61 1.2k
Marzieh Araghi Sweden 11 68 0.2× 219 0.7× 152 0.5× 40 0.1× 89 0.5× 17 792
Masao Nakabayashi Japan 20 80 0.2× 73 0.2× 108 0.4× 128 0.5× 146 0.8× 68 1.2k
Jie Shi China 11 99 0.3× 152 0.5× 40 0.1× 28 0.1× 33 0.2× 37 582
Cheryl A. Black United States 13 34 0.1× 423 1.4× 238 0.8× 83 0.3× 254 1.5× 25 1.1k
Xiaoli Chen China 17 48 0.1× 172 0.6× 90 0.3× 30 0.1× 33 0.2× 34 861
Xin Zhong China 14 88 0.3× 87 0.3× 321 1.1× 43 0.2× 22 0.1× 36 911
Mahmoud Parvin Iran 17 110 0.3× 49 0.2× 214 0.7× 75 0.3× 12 0.1× 63 834

Countries citing papers authored by James Roach

Since Specialization
Citations

This map shows the geographic impact of James Roach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Roach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Roach more than expected).

Fields of papers citing papers by James Roach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Roach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Roach. The network helps show where James Roach may publish in the future.

Co-authorship network of co-authors of James Roach

This figure shows the co-authorship network connecting the top 25 collaborators of James Roach. A scholar is included among the top collaborators of James Roach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Roach. James Roach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Foster, William J., et al.. (2022). A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution. Drugs in R&D. 23(1). 43–53. 1 indexed citations
2.
O’Reilly, Eileen M., Devalingam Mahalingam, Tanios Bekaii‐Saab, et al.. (2020). Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. European Journal of Cancer. 132. 112–121. 27 indexed citations
3.
Hava, David L., Patrick W. Johnson, Aidan K. Curran, et al.. (2019). A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. British Journal of Clinical Pharmacology. 86(4). 723–733. 23 indexed citations
4.
Harrill, Alison H., James Roach, J. Scott Eaddy, et al.. (2012). The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 92(2). 214–220. 89 indexed citations
5.
Long, Alison, Ishan Capila, Ram Sasisekharan, et al.. (2009). M118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thrombosis and Haemostasis. 102(11). 900–906. 10 indexed citations
6.
Roth, Thomas, J. M. Price, David A. Amato, et al.. (2009). The Effect of Eszopiclone in Patients With Insomnia and Coexisting Rheumatoid Arthritis. The Primary Care Companion to The Journal of Clinical Psychiatry. 11(6). 292–301. 33 indexed citations
7.
Melloni, Chiara, James Roach, Andrzej S. Kosinski, et al.. (2009). Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. American Heart Journal. 158(5). 726–733. 3 indexed citations
8.
Donohue, James F., Nicola A. Hanania, Ronald L. Ciubotaru, et al.. (2008). Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clinical Therapeutics. 30. 989–1002. 15 indexed citations
9.
Pollack, Mark H., Gustavo Kinrys, Andrew D. Krystal, et al.. (2008). Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder. Archives of General Psychiatry. 65(5). 551–551. 104 indexed citations
10.
Rosenberg, Russell, James Roach, Martin B. Scharf, & David A. Amato. (2007). A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Medicine. 8(5). 464–470. 71 indexed citations
11.
Walsh, James K., Andrew D. Krystal, David A. Amato, et al.. (2007). Nightly Treatment of Primary Insomnia With Eszopiclone for Six Months: Effect on Sleep, Quality of Life, and Work Limitations. SLEEP. 30(8). 959–968. 167 indexed citations
12.
13.
Skoner, David P., et al.. (2005). Evaluation of the Safety and Efficacy of Levalbuterol in 2-5-year-Old Patients with Asthma. Pediatric Pulmonology. 40(6). 477–486. 29 indexed citations
14.
Hanania, Nicola A., et al.. (2004). FEV1 Response to Levalbuterol vs Racemic Albuterol in Acute Severe Asthma. CHEST Journal. 126(4). 722S–722S. 1 indexed citations
15.
Nowak, Richard M., et al.. (2004). Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. The American Journal of Emergency Medicine. 22(1). 29–36. 38 indexed citations
16.
Roach, James, Stephen R. Muza, Paul Rock, et al.. (1996). Urinary Leukotriene E4 Levels Increase Upon Exposure to Hypobaric Hypoxia. CHEST Journal. 110(4). 946–951. 12 indexed citations
17.
Roach, James, et al.. (1994). Refractory Period During Provocation with Eucapnic Hyperventilation and Methacholine. American Journal of Respiratory and Critical Care Medicine. 149(6). 1452–1456. 6 indexed citations
18.
Roach, James, et al.. (1994). Eucapnic Voluntary Hyperventilation as a Bronchoprovocation Technique. CHEST Journal. 105(3). 667–672. 11 indexed citations
19.
Roach, James, et al.. (1993). The Effect of Pyridostigmine on Bronchial Hyperreactivity. CHEST Journal. 103(6). 1755–1758. 7 indexed citations
20.
Roach, James, Karl C. Stajduhar, & Kenneth G. Torrington. (1993). Right Upper Lobe Pulmonary Edema Caused by Acute Mitral Regurgitation. CHEST Journal. 103(4). 1286–1288. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gail Murphy Breakdown of academic impact, for papers by Heiner Mönig Breakdown of academic impact, for papers by Marzieh Araghi Breakdown of academic impact, for papers by Masao Nakabayashi Breakdown of academic impact, for papers by Jie Shi Breakdown of academic impact, for papers by Cheryl A. Black Breakdown of academic impact, for papers by Xiaoli Chen Breakdown of academic impact, for papers by Xin Zhong Breakdown of academic impact, for papers by Mahmoud Parvin
Rankless by CCL
2026